SCHEMBL2523705

SCHEMBL2523705

CC(C)(C)OC(=O)N1CCCN(Cc2ccc(O)c3ncccc23)CCN(C(=O)OC(C)(C)C)CCCN(Cc2cccc(CN3CCCN(C(=O)O)C(C(C)(C)C)C(C(C)(C)C)N(C(=O)O)C(C(C)(C)C)CCN(C(=O)O)CC3)c2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.46
KDM4E B2RXH2 6/20 0.46
KMT2A Q03164 4/20 0.46
L3MBTL1 Q9Y468 4/20 0.46
ALDH1A1 P00352 3/20 0.46
MPI P34949 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
APP P05067 10/20 0.43
NFKB1 P19838 4/20 0.43
NFKB2 Q00653 4/20 0.43
RELA Q04206 4/20 0.43
TP53 P04637 3/20 0.43
USP2 O75604 1/20 0.43
ALOX15 P16050 1/20 0.43
SMN1; SMN2 Q16637 3/20 0.40
NPC1 O15118 2/20 0.40
MEN1 O00255 1/20 0.40
BLM P54132 1/20 0.40
ALOX12 P18054 3/20 0.40
NPSR1 Q6W5P4 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2525125 0.89 KDM4E (0.50) MAPTKDM4EKMT2AL3MBTL1ALDH1A1
SCHEMBL2523698 0.85 MAPT (0.63) MAPTKDM4EKMT2AL3MBTL1ALDH1A1
SCHEMBL2523696 0.83 MAPT (0.46) MAPTKDM4EKMT2AL3MBTL1ALDH1A1
SCHEMBL2521716 0.80 KDM4E (0.53) MAPTKDM4EKMT2AL3MBTL1ALDH1A1
SCHEMBL2521161 0.80 MAPT (0.71) MAPTKDM4EKMT2AL3MBTL1ALDH1A1
SCHEMBL2518215 0.80 MAPT (0.71) MAPTKDM4EKMT2AL3MBTL1ALDH1A1
SCHEMBL2518129 0.79 MAPT (0.69) MAPTKDM4EKMT2AL3MBTL1ALDH1A1
SCHEMBL5594397 0.76 MAPT (0.77) MAPTKDM4EKMT2AL3MBTL1ALDH1A1
SCHEMBL2523503 0.72 KDM4E (0.50) MAPTKDM4EKMT2AL3MBTL1ALDH1A1
SCHEMBL2525120 0.70 KDM4E (0.50) MAPTKDM4EKMT2AL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110251238-A1 PPAR AGONIST COMPOSITIONS AND METHODS OF USE BIOPHARMED (FR) 2011-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251238-A1 PPAR AGONIST COMPOSITIONS AND METHODS OF USE PPARA, PPARG, PPARD MAPT 4323/4885KDM4E 4239/4885KMT2A 3167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.